A Aralex Aachen research explorer

Company ROR OpenAlex

Galapagos (Netherlands) Sign in to save

159 stored papers · Search its papers → · Its authors →

Papers 159

RNA SEQUENCING REVEALS NOVEL MARKERS AND PATHWAYS OF T3-INDUCED CARTILAGE HYPERTROPHY
2022 Osteoarthritis and Cartilage article Medicine Osteoarthritis Treatment and Mechanisms Open access

0

citations
P192 Efficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials
2022 Lara D. Veeken article Medicine Rheumatoid Arthritis Research and Therapies Open access

0

citations
POS0658 GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

0

citations
P47 Re-treatment with filgotinib in patients with ulcerative colitis following treatment interruption: SELECTION and SELECTIONLTE data
2022 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

0

citations
P45 Combining clinical, biological, and health-related quality of life remission with endoscopic improvements: data from SELECTION
2022 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

0

citations
POS0704 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

0

citations
Development of an amplicon nanopore sequencing strategy for detection of mutations conferring intermediate resistance to vancomycin in Staphylococcus aureus strains
2022 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine Antimicrobial Resistance in Staphylococcus Open access

0

citations
P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study
2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

0

citations
DOP45 Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
2023 Journal of Crohn s and Colitis article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

0

citations
P736 Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial
2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

0

citations
P624 Investigating the symptom burden among European patients with moderate-to-severe Crohn’s disease using a real-world survey
2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

0

citations
Supplemental Figures S1-S5 from SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer
2023 supplementary-materials Medicine Prostate Cancer Treatment and Research Open access

0

citations
Supplemental Figures S1-S5 from SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer
2023 supplementary-materials Medicine Prostate Cancer Treatment and Research Open access

0

citations
Implementation and Performance of a Standardized 6-minute Walk Test in Idiopathic Pulmonary Fibrosis: Results From the Isabela Studies
2023 conference-abstract Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

0

citations
O63 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among SELECTIONLTE patients with ulcerative colitis
2023 Oral Presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

0

citations
P57 Predicting late responders to filgotinib in patients with ulcerative colitis: a post hoc analysis of SELECTION and SELECTIONLTE
2023 Poster presentations conference-paper Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

0

citations
P56 Prolonged benefit of filgotinib in patients with ulcerative colitis in SELECTION
2023 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

0

citations
O35 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme
2023 Oral Presentations conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

0

citations
Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions
2023 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments Open access

0

citations
P772 Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trial
2024 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

0

citations

Most cited authors